MTNB Matinas BioPharma
- 0.1757
- +0.0051+2.99%
- 0.1750
- -0.0007-0.40%
Matinas BioPharma News
Buy Rating Affirmed for Matinas BioPharma on Strong Financials and Promising Oral Antifungal Candidate
Q1 2024 Matinas BioPharma Holdings Inc Earnings Call
Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call Transcript
Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call Transcript
Matinas BioPharma Hldgs Q1 2024 GAAP EPS $(0.03), Inline
Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate.
Press Release: Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update Recent $10 million financing expected to fund planned development programs and operations into the second
Matinas BioPharma 1Q Loss/Shr 3c >MTNB
Matinas BioPharma 1Q Loss/Shr 3c >MTNB
Matinas BioPharma | 10-Q: Quarterly report
Matinas BioPharma's LNC Platform For The Delivery Of Small Oligonucleotides Featured In Two Presentations At The ASGCT Annual Meeting
Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology,
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal
In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
Studies in neutropenic mouse model demonstrate prolonged and enhanced survival, reduced fungal burden and improvement in lung infectionBEDMINSTER, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Matinas Bi
Matinas BioPharma's Multi-Million Share Sale and Lock-Up Deal
Matinas BioPharma Prices $10 Million Registered Direct Offering
BEDMINSTER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) ("Matinas BioPharma" or the "Company"), a clinical-stage biopharmaceutical company focused on delivering groundbreaking
Matinas BioPharma (MTNB) Gets a Buy From Maxim Group
12 Health Care Stocks Moving In Monday's After-Market Session
GainersOpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. The market value of their outstanding shares is at $7.4 million. Galecto (NASDAQ:GLTO) shares in
Earnings Call Summary | Matinas BioPharma(MTNB.US) Q4 2023 Earnings Conference
The following is a summary of the Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript:Financial Performance:Matinas BioPharma reported a revenue of $1.1 million for 2023, primaril
Matinas BioPharma Updates Presentation for Investor Outreach
Matinas BioPharma Hldgs Q4 EPS $(0.03) Down From $(0.02) YoY
Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.03) per share. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year.
Matinas Biopharma GAAP EPS of -$0.11, Revenue of $1.1M
Matinas BioPharma FY23 EPS $(0.11) Vs $(0.10) YoY
2023 Financial ResultsRevenue for 2023 was $1.1 million, which was generated from the Company's research collaborations with BioNTech SE and Genentech Inc. This compares with revenue for 2022 of $3.2
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) reports 2023 financial results and provides a business update.
Analysis
Price Target
No Data
